Kenneth Galbraith - 22 Dec 2025 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Role
Chair & CEO, Director
Signature
/s/ Daniel Dex, Attorney-in-Fact
Issuer symbol
ZYME
Transactions as of
22 Dec 2025
Net transactions value
-$1,284,311
Form type
4
Filing time
22 Dec 2025, 17:52:15 UTC
Previous filing
10 Jan 2025
Next filing
05 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Galbraith Kenneth Chair & CEO, Director C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN /s/ Daniel Dex, Attorney-in-Fact 22 Dec 2025 0001567045

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYME Common Stock Options Exercise $0 +100,000 +124% $0.000000 180,803 22 Dec 2025 Direct F1
transaction ZYME Common Stock Sale $1,284,311 -47,528 -26% $27.02 133,275 22 Dec 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Restricted Stock Unit Options Exercise $0 -100,000 -100% $0.000000 0 22 Dec 2025 Common Stock 100,000 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issued upon vesting of restricted stock units ("RSUs") granted on December 22, 2022.
F2 Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.83 to $27.16 inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F5 The RSUS vested on December 22, 2025.